April 4 (Reuters) - Boehringer Ingelheim on Thursday said it will lay off some of its salesforce due ... with the same prices as Boehringer and Amgen, whose Amjevita was the first Humira ...
In recent years, Amgen has been using acquisitions as a way to bolster its competitive position. And that's the big unknown for investors going forward: whether its recent purchases will pay off.
Amgen's shares have gotten off to a rocky start in 2024. Since the start of the year, the biotech's stock price has fallen by a hefty 8% compared to a nearly 7% gain for the S&P 500. Amgen's stock ...
Just last week, Tesla laid off yet another round of workers. This time, however, Tesla gutted an entire team. Around 500 ...
Some experts say the recommended doses for drugs like sotorasib are too high, and they are advocating for a change in how cancer drugs are dosed. They want to do away with the concept of the maximum ...
all of the hard work that doctors and scientists have done in this space is starting to pay off. It's still early in the KRAS time table with regard to in-human studies, but Amgen could be sitting ...
Researchers including the team at Columbia and drugmakers are trying to solve the biggest problem in the weight-loss industry ...
The move comes after the Elon Musk-led automaker disbanded its EV charging department following Tesla’s announcement last ...
As with Epogen, the initial discoveries that laid the basis for the drug had ... That decade of investment and research was paying off. In 1992, Amgen hit the billion dollars sales mark and ...
Electric-vehicle maker Tesla has laid off staff from the software, service and engineering departments, tech publication Electrek reported on Monday, citing sources familiar with the matter.
Amgen's acquisition of Horizon Therapeutics has made it a major player in the rare disease space, with potential for long-term shareholder return. The company has key pipeline milestones in 2024 ...